JP2018516932A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516932A5
JP2018516932A5 JP2017562678A JP2017562678A JP2018516932A5 JP 2018516932 A5 JP2018516932 A5 JP 2018516932A5 JP 2017562678 A JP2017562678 A JP 2017562678A JP 2017562678 A JP2017562678 A JP 2017562678A JP 2018516932 A5 JP2018516932 A5 JP 2018516932A5
Authority
JP
Japan
Prior art keywords
amino
sulfonyl
phenyl
pyridine
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017562678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516932A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/000821 external-priority patent/WO2016193812A1/en
Publication of JP2018516932A publication Critical patent/JP2018516932A/ja
Publication of JP2018516932A5 publication Critical patent/JP2018516932A5/ja
Pending legal-status Critical Current

Links

JP2017562678A 2015-06-02 2016-05-25 置換ピリジンおよび使用方法 Pending JP2018516932A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169881P 2015-06-02 2015-06-02
US62/169,881 2015-06-02
PCT/IB2016/000821 WO2016193812A1 (en) 2015-06-02 2016-05-25 Substituted pyridines and method of use

Publications (2)

Publication Number Publication Date
JP2018516932A JP2018516932A (ja) 2018-06-28
JP2018516932A5 true JP2018516932A5 (enExample) 2019-06-27

Family

ID=57440295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017562678A Pending JP2018516932A (ja) 2015-06-02 2016-05-25 置換ピリジンおよび使用方法

Country Status (23)

Country Link
US (1) US10047051B2 (enExample)
EP (1) EP3303294A1 (enExample)
JP (1) JP2018516932A (enExample)
KR (1) KR20180029204A (enExample)
CN (1) CN107922338A (enExample)
AR (1) AR106865A1 (enExample)
AU (1) AU2016272702A1 (enExample)
BR (1) BR112017026132A2 (enExample)
CA (1) CA2988046A1 (enExample)
CL (1) CL2017003067A1 (enExample)
CO (1) CO2017012566A2 (enExample)
CR (1) CR20170595A (enExample)
DO (1) DOP2017000278A (enExample)
EC (1) ECSP17085494A (enExample)
HK (1) HK1253581A1 (enExample)
IL (1) IL256032A (enExample)
MX (1) MX2017015591A (enExample)
PE (1) PE20180457A1 (enExample)
PH (1) PH12017502201A1 (enExample)
RU (1) RU2017146661A (enExample)
TW (1) TW201713621A (enExample)
UY (1) UY36702A (enExample)
WO (1) WO2016193812A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210401869A1 (en) * 2015-02-20 2021-12-30 Rosalind Franklin University Of Medicine And Science Antisense Compounds Targeting Genes Associated with Cystic Fibrosis
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
JP2022519301A (ja) * 2019-02-06 2022-03-22 ノバルティス アーゲー N-(ピリジン-2-イル)ピリジン-スルホンアミド誘導体及び疾患の処置におけるそれらの使用
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2021011327A1 (en) 2019-07-12 2021-01-21 Orphomed, Inc. Compound for treating cystic fibrosis
MX2022005810A (es) 2019-11-12 2022-06-08 Genzyme Corp Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente.
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113808A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Cftr-modulating arylamides
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CA3223599A1 (en) 2021-08-19 2023-02-23 Peter FINKBEINER Method for controlling diamide resistant pests & compounds therefor
WO2023034946A1 (en) * 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
IL319374A (en) 2022-09-07 2025-05-01 Sionna Therapeutics Inc Macrocyclic compounds, compositions and methods of using them

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120497A2 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CN101687883B (zh) 2007-05-25 2012-05-23 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
ES2422741T3 (es) 2007-12-13 2013-09-13 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
NZ592504A (en) 2008-10-23 2013-04-26 Vertex Pharma Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (ja) * 2011-09-16 2017-07-19 ノバルティス アーゲー N−置換ヘテロシクリルカルボキサミド類
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
BR112014006535A2 (pt) 2011-09-20 2017-03-28 Univ North Carolina Chapel Hill regulação dos canais de sódio através das proteínas plunc
CA3122383A1 (en) * 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
AU2014304562B8 (en) 2013-08-08 2018-07-05 Galapagos Nv Thieno[2,3-c]pyrans as CFTR modulators
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
AU2015229117A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
AU2017264612A1 (en) * 2016-05-09 2018-11-22 Proteostasis Therapeutics, Inc. Methods of identifying CFTR modulators

Similar Documents

Publication Publication Date Title
RU2017146661A (ru) Замещенные пиридины и способ их применения
RU2015143917A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний
JP2014521696A5 (enExample)
JP2017530999A5 (enExample)
RU2011127402A (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
RU2017116598A (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
RU2451674C2 (ru) Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1
RU2347777C2 (ru) Двойные агонисты nk1/nk3 для лечения шизофрении
JP5518838B2 (ja) ピロリジノングルコキナーゼアクチベーター
JP2015529192A5 (enExample)
AU2014291711B2 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
JP2022554169A5 (enExample)
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
GB2583882A (en) Compounds
RU2001126337A (ru) Соединения, пригодные в качестве противовоспалительных агентов
JP6074043B2 (ja) 新規なモルホリン誘導体またはその塩
JP2012532888A5 (enExample)
ME02205B (me) INDUKUJUĆI AGENSI APOPTOZE ZA LEČENJE KANCERA I IMUNIH l AUTOIMUNIH OBOLJENJA
HRP20240297T1 (hr) Derivati alfa-d-galaktopiranozida
RU2014108140A (ru) Соединение на основе хинозолина в качестве ингибиторов серен-треониновых киназ
CN109923113A (zh) 作为GABA A α5 PAM的新型异噁唑基醚衍生物
JP2016503009A5 (enExample)
JP2018505145A5 (enExample)
RU2019123319A (ru) Пиразолопиримидины и способы их применения
RU2015120217A (ru) Замещенные 1,6-нафтиридины